uniQure N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QURE Nasdaq 2836 www.uniqure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for uniQure N.V.

Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? - Jan 12th, 2026 8:11 am
uniQure Announces Type A Meeting Scheduled with FDA - Jan 9th, 2026 5:05 am
What Do Analysts Think About UniQure (QURE)? - Dec 21st, 2025 7:56 am
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Dec 15th, 2025 9:11 pm
uniQure (QURE): Reassessing Valuation After FDA Doubts on AMT-130’s Path to Approval - Dec 5th, 2025 5:19 pm
uniQure N.V. (QURE): A Bear Case Theory - Dec 4th, 2025 10:18 am
UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy - Dec 4th, 2025 8:02 am
Wall Street Cautious as Key Inflation Report Looms, Driving Muted Premarket Action for US Equity Futures - Dec 4th, 2025 7:18 am
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - Dec 4th, 2025 5:05 am
William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty - Nov 25th, 2025 6:39 am
Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 - Nov 19th, 2025 6:16 am
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - Nov 17th, 2025 10:15 am
uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Nov 15th, 2025 5:07 am
Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Nov 13th, 2025 3:30 am
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - Nov 12th, 2025 5:00 am
uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges - Nov 10th, 2025 2:01 pm
uniQure (QURE) Q3 2025 Earnings Call Transcript - Nov 10th, 2025 7:57 am
uniQure (QURE) Is Down 19.0% After FDA Questions Data for AMT-130 Gene Therapy Approval Pathway – Has The Bull Case Changed? - Nov 10th, 2025 7:12 am
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2025 6:15 am
UniQure: Q3 Earnings Snapshot - Nov 10th, 2025 5:14 am